Novo Nordisk Boosts Specialty R&D With Kidney Disease Deal

 
• By John Davis

Denmark's diabetes specialty company has linked up with a US biotech to evaluate a lysophosphatidic acid receptor antagonist in diabetic and chronic kidney disease.  

Teamwork
Novo Nordisk has licensed a small-molecule program • Source: Shutterstock

More from Deals

More from Business